Stock NBY NOVABAY PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NovaBay Pharmaceuticals, Inc.

Equities

NBY

US66987P4090

Market Closed - Nyse
Other stock markets
 16:00:00 2024-06-14 EDT 		5-day change 1st Jan Change
2.51 USD -2.33% Intraday chart for NovaBay Pharmaceuticals, Inc. -7.38% -64.85%
05-09 NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-09 Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
BU
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
BU
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
BU
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
BU
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
BU
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
AQ
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
BU
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
BU
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
BU
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
BU
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
BU
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K
PU
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
BU
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
AQ
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
BU
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
AQ
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
BU
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union through Sonoma's Extensive Distributor Network
AQ
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
BU
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBY Stock
  4. News NovaBay Pharmaceuticals, Inc.
  5. Press Releases